Clinical-stage biopharmaceutical company atai Life Sciences N.V. (Nasdaq: ATAI) revealed that it has bagged clearance from the U.S. Food and Drug Administration (FDA) to conduct a clinical DDI study of PCN-101, designed to treat mental health disorders. The company seeks to begin the study early in 2022 through its platform company Perception Neuroscience. atai Life Sciences expects that PCN-101 carries some unique properties that are different from currently available antidepressants and has the potential to address key patient needs, including the potential of rapid action and anti-suicidal effect.
https://www.tipranks.com/news/atai-life-sciences-bags-fda-nod-for-pcn-101-clinical-trials?utm_source=advfn.com&utm_medium=referral
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more ATAI Life Sciences NV Charts.
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more ATAI Life Sciences NV Charts.